Faculty Information - FUKUDA Hironori

（Last updated : 2026-08-10 09:48:12）

FUKUDA Hironori
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2.	Original article	Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3.	Other	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. 2026/05
4.	Other	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. 2026/05
5.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
6.	Case report	Requiring caution in the interpretation of donor- derived cell- free DNA levels during cancer treatment in a kidney transplant recipient.: A case report 2026/05
7.	Original article	Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
8.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
9.	Original article	Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations. 2026/03
10.	Original article	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
11.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
12.	Original article	Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
13.	Case report	Safety of enfortumab vedotin plus pembrolizumab in hemodialysis patients with metastatic urothelial carcinoma: Case report 2025/09/01
14.	Original article	Impact of polypharmacy on perioperative outcomes of robot‐assisted laparoscopic partial nephrectomy for small renal masses. 2025/09
15.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
16.	Original article	Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
17.	Case report	Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases. 2025/08
18.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
19.	Other	Relative changes in donor-derived cell-free DNA as a marker of allograft rejection in a kidney transplant recipient with metastatic cancer undergoing immunotherapy 2025/08
20.	Original article	Genome-wide transcriptome and DNA methylome profiling of acquired cystic disease-associated renal cell carcinoma. 2025/06
21.	Other	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. 2025/05
22.	Other	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. 2025/05
23.	Other	Gene profile of old donor kidney related to kidney function before and after kidney transplantation. 2025/05
24.	Other	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2025/05
25.	Other	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2025/05
26.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
27.	Original article	Comparing surgical outcomes between robot-assisted laparoscopic and open partial nephrectomy for allograft kidney tumors: a retrospective, single-center study. 2025/03
28.	Original article	Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
29.	Original article	Unveiling spatial immune cell profile in kidney allograft rejections using 36-plex immunofluorescence imaging. 2024/12
30.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
31.	Original article	Robot-assisted partial nephrectomy for multiple allograft renal cell carcinomas: A case report. 2024/11
32.	Original article	Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis. 2024/10
33.	Case report	Effectiveness of robot-assisted adrenalectomy for a giant adrenal hemangioma: A case report. 2024/09
34.	Original article	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/09
35.	Original article	Comparison of surgical outcomes of robot‑assisted laparoscopic partial nephrectomy performed by a single experienced surgeon according to two reconstruction methods, including single‑layer and double‑layer renorrhaphy. 2024/07/27
36.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
37.	Original article	Robot-assisted partial nephrectomy with selective artery clamping for renal cell carcinoma in horseshoe kidney. 2024/07
38.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
39.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
40.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
41.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
42.	Original article	Surgical and functional outcomes of repeat robot-assisted laparoscopic partial nephrectomy compared with repeat open partial nephrectomy. 2024/04
43.	Case report	Advanced renal cell carcinoma with Inferior vena cava thrombus treated with a combination of preoperative lenvatinib and pembrolizumab. 2024/03
44.	Original article	Comparisons of survival and surgical outcomes between minimally invasive partial nephrectomy and radical nephrectomy in elderly patients with stage 1 renal cell carcinoma. 2024/03
45.	Original article	Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2024/02
46.	Original article	Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
47.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
48.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
49.	Original article	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/07
50.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
51.	Case report	Long-time survival of a renal transplant recipient with metastatic mucinous tubular and spindle cell carcinoma: A case report. 2023/05
52.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
53.	Original article	Efficacy of combined pembrolizumab and pelvic radiotherapy for bladder cancer with rectal metastases. 2023/03
54.	Original article	Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
55.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
56.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
57.	Original article	Analyses of operative time according to procedure phases during robot-assisted laparoscopic partial nephrectomy using the iPhone application “My Intuitives” 2022/11
58.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
59.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
60.	Original article	Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma. 2022/04
61.	Original article	Role of fractalkine-CX3CR1 axis in acute rejection of mouse heart allografts subjected to ischemia reperfusion injury 2022/02/01
62.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
63.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
64.	Original article	Assessment of Feasibility of Robot-assistted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy 2022
65.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
66.	Original article	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. 2021/12
67.	Original article	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. 2021/10
68.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
69.	Original article	Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
70.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
71.	Original article	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
72.	Original article	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
73.	Original article	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. 2021/04
74.	Original article	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
75.	Original article	Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
76.	Original article	The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
77.	Original article	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
78.	Original article	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
79.	Original article	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
80.	Case report	Total nephroureterocystectomy and urethrectomy due to urothelial carcinoma associated with the BK polyomavirus infection after kidney transplantation: a case report with literature review. 2020/11
81.	Original article	Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? 2020/08
82.	Original article	The de ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. 2020/06
83.	Original article	Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
84.	Original article	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. 2020/05
85.	Original article	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. 2020/05
86.	Original article	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
87.	Original article	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
88.	Original article	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
89.	Original article	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
90.	Original article	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. 2019/06
91.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
92.	Original article	Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. 2019/04
93.	Original article	A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion. 2019/03
Display 5 items
Display all(93)

■ Academic conference presentation

1.	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. （Poster notice，General） 2026/05/18
2.	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice，General） 2026/05/18
3.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （Poster notice，General） 2026/05/18
4.	Association of Serum Kidney Injury Molecule-1 with Treatment Response and Survival in Metastatic Renal Cell Carcinoma. （Speech，General） 2026/04/25
5.	Real-world experience with adjuvant pembrolizumab toxicities in renal cell carcinoma: A single-center experience at Tokyo Women's Medical University. （Speech，General） 2026/04/24
6.	Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
7.	Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
8.	Novel peripheral blood immune clustering predicts prognosis and T cell exhaustion in renal cell carcinoma. （Poster notice，General） 2026/04/23
9.	Prognostic significance of B Cell and NK cell infiltration in the tumor immune microenvironment of renal cell carcinoma. （Poster notice，General） 2026/04/23
10.	Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma. （Poster notice，General） 2026/02/28
11.	Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma. （Poster notice，General） 2026/02/28
12.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
13.	Relative changes in donor-derived cell-free DNA as a marker of allograft rejection in a kidney transplant recipient with metastatic cancer undergoing immunotherapy. （Poster notice，General） 2025/08/05
14.	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （Poster notice，General） 2025/04/28
15.	Gene profile of old donor kidney related to kidney function before and after kidney transplantation. （Poster notice，General） 2025/04/28
16.	Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （Poster notice，General） 2025/04/28
17.	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. （Poster notice，General） 2025/04/27
18.	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. （Poster notice，General） 2025/04/26
19.	Clinical outcomes of repeat robot-assisted partial nephrectomy compared to repeat open partial nephrectomy. （Speech，General） 2025/03/23
20.	Molecular basis of immune suppressive microenvironment specified by cancer-associated fibroblasts in pancreatic cancer. （Speech，General） 2024/09/21
21.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
22.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
23.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （Poster notice） 2024/04/26
24.	BRCA mutation-positive prostate cancer at our hospital initial experience with olaparib in BRCA mutation-positive prostate cancer. （Poster notice，General） 2024/04/26
25.	Efficiency of IO-IO combination therapy and IO-TKI combination therapy for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice） 2024/04/26
26.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
27.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （Poster notice） 2024/04/26
28.	Primary renal tumor response in patients treated with first-line systemic therapy for advanced renal cell carcinoma. （Poster notice，General） 2024/04/26
29.	Utility of whole-body MRI (DWIBS) in treatment decision-making for M0CRPC: A case series study. （Poster notice，General） 2024/04/26
30.	Comparison of Perioperative Outcomes between Robot-Assisted Laparoscopic Radical Nephroureterectomy and Laparoscopic Radical Nephroureterectomy. （Poster notice） 2024/04/25
31.	Comparison of surgical outcomes between robot-assisted and conventional laparoscopic adrenalectomy at Tokyo Women's Medical University Hospital. （Poster notice，General） 2024/04/25
32.	Comparisons of surgical outcomes of robot-assisted laparoscopic partial nephrectomy according to reconstruction methods, including single-layer and double-layer renorraphy: Analyses of an experienced surgeon. （Speech，General） 2024/04/08
33.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
34.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
35.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy： Real-world data from Japanese single high-volume center. （Poster notice，General） 2023/04/29
36.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. （Poster notice，General） 2023/04/29
37.	Initial experiences of robot-assisted adrenalectomy. （Poster notice，General） 2023/04/22
38.	Medication states of up-front ARAT treatment for mHSPC in real-world practice. （Poster notice，General） 2023/04/21
39.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy: Real-world data from Japanese single high-volume center. （Speech，General） 2023/04/21
40.	Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). A clinicopathological study of 10 Japanese cases. （Poster notice，General） 2023/04/21
41.	CODEX multiplex immune-staining Identifies novel spatial indexes for antibody-mediated rejection diagnosis. （Poster notice） 2023/04/20
42.	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. （Speech，General） 2023/04/20
43.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
44.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
45.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
46.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
47.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
48.	Association between controlling nutritional status（CONUT）score and outcomes after radical cystectomy for advanced bladder cancer. （Speech，General） 2020/12/23
49.	Association between early tumor response and survival in metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2020/12/23
50.	Comparison of efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2020/12/23
51.	The predictive impact of presurgical sarcopenia on patient survival in patients with renal cell carcinoma with inferior vena cava tumor thrombus. （Speech，General） 2020/12/23
52.	Retroperitoneal approach is better quality of recovery than transperitoneal approach after robot-assisted partial nephrectomy. （Poster notice，General） 2020/12/22
53.	Cancer-associated fibroblast recruited a specific subset of myeloidderived suppressor cells to pancreatic cancer tissue. （Poster notice，General） 2020/10/01
54.	Genetic and epigenetic profiling reveals the proximal tubule origin of renal cancers in end-stage renal disease. （Poster notice，General） 2020/10/01
55.	Comparisons of surgical outcomes between transperitoneal and retroperitoneal　approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: A propensity score-matched comparative analysis. （Speech，General） 2020/07/17
56.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoingrobot-assisted partial nephrectomy, using enhanced CT. （Speech，General） 2020/07/17
57.	Predictive factors for recurrence after complete metastasectomy in patients with metastaticrenal cell carcinoma in the targeted therapy era. （Speech，General） 2020/07/17
58.	Usefulness of robot-assisted laparoscopic partial nephrectomy using trifecta criteria. （Poster notice，General） 2020/07/17
59.	The role of pancreatic cancer associated fibroblasts to construct immune suppressive microenvironment. （Poster notice，General） 2019/09/26
60.	Fractalkine is crucial in ischemia reperfusion injury related to acute rejection in an allogeneic heart transplantation model. （Poster notice，General） 2019/06/02
61.	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib herapy for metastatic renal cell carcinoma. （Poster notice，General） 2019/05/04
62.	Long-term follow-up of renal function and development of chronic kidney disease after partial nephrectomy. （Poster notice，General） 2019/05/04
63.	Association of immune-related adverse events with prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2019/05/03
64.	The clinical benefit of metastasectomy in renal cell carcinoma in the ERA of targeted molecular therapy. （Speech，General） 2014/09/06
65.	Limited benefit of targeted therapies on ivc thrombus in renal cell carcinoma. （Poster notice，General） 2014/05/19
66.	Impact Of Preoperative C-Reactive Protein On Survival Of Patients On Chronic Hemodialysis Undergoing Nephrectomy For Renal Cell Carcinoma （Speech，General） 2013/08/31
67.	The Clinical Benefit of Targeted Therapies On IVC Thrombus Of Renal Cell Carcinoma （Speech，General） 2013/08/31
Display 5 items
Display all(67)

■ Research areas

Urology (Key Word：Urology)

■ Education

2015/04～2019/03

〔Doctoral course〕〔Doctorial Course〕 Urology, Graduate School, Division of Medical Sciences, Tokyo Women's Medical University, Completed, PhD